Solventum Corp.
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates in three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions for negative pressure wound therapy, advanced wound dressings, advance… Read more
Solventum Corp. (SOLV) - Net Assets
Latest net assets as of September 2025: $4.99 Billion USD
Based on the latest financial reports, Solventum Corp. (SOLV) has net assets worth $4.99 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.97 Billion) and total liabilities ($8.99 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.99 Billion |
| % of Total Assets | 35.68% |
| Annual Growth Rate | -37.39% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 34.42 |
Solventum Corp. - Net Assets Trend (2021–2024)
This chart illustrates how Solventum Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Solventum Corp. (2021–2024)
The table below shows the annual net assets of Solventum Corp. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.96 Billion | -74.64% |
| 2023-12-31 | $11.67 Billion | -0.65% |
| 2022-12-31 | $11.74 Billion | -2.63% |
| 2021-12-31 | $12.06 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Solventum Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 24200000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $242.00 Million | 8.18% |
| Common Stock | $2.00 Million | 0.07% |
| Other Comprehensive Income | $-1.06 Billion | -35.69% |
| Other Components | $3.77 Billion | 127.44% |
| Total Equity | $2.96 Billion | 100.00% |
Solventum Corp. Competitors by Market Cap
The table below lists competitors of Solventum Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Poste Italiane S.p.A.
LSE:0RC2
|
$9.91 Billion |
|
SPX Corp
NYSE:SPXC
|
$9.91 Billion |
|
Rambus Inc
NASDAQ:RMBS
|
$9.92 Billion |
|
Ally Financial Inc
NYSE:ALLY
|
$9.95 Billion |
|
Uni-President Enterprises Corp
TW:1216
|
$9.88 Billion |
|
Plains All American Pipeline LP
NASDAQ:PAA
|
$9.88 Billion |
|
Computershare Ltd
AU:CPU
|
$9.88 Billion |
|
Fisher & Paykel Healthcare Corporation Limited
PINK:FSPKF
|
$9.88 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Solventum Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,666,000,000 to 2,959,000,000, a change of -8,707,000,000 (-74.6%).
- Net income of 479,000,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 719,000,000.
- Other factors decreased equity by 8,467,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $479.00 Million | +16.19% |
| Other Comprehensive Income | $-719.00 Million | -24.3% |
| Other Changes | $-8.47 Billion | -286.14% |
| Total Change | $- | -74.64% |
Book Value vs Market Value Analysis
This analysis compares Solventum Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.94x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.96x to 3.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $69.92 | $67.14 | x |
| 2022-12-31 | $68.08 | $67.14 | x |
| 2023-12-31 | $67.55 | $67.14 | x |
| 2024-12-31 | $17.04 | $67.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Solventum Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.19%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.80%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 4.89x
- Recent ROE (16.19%) is above the historical average (12.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 12.11% | 17.87% | 0.58x | 1.17x | $254.10 Million |
| 2022 | 11.44% | 16.52% | 0.60x | 1.16x | $168.80 Million |
| 2023 | 11.54% | 16.42% | 0.59x | 1.20x | $179.40 Million |
| 2024 | 16.19% | 5.80% | 0.57x | 4.89x | $183.10 Million |
Industry Comparison
This section compares Solventum Corp.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,344,700,045
- Average return on equity (ROE) among peers: -67.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Solventum Corp. (SOLV) | $4.99 Billion | 12.11% | 1.80x | $9.89 Billion |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $520.03 Million | 8.62% | 0.25x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $121.35 Million | -35.38% | 0.57x | $16.24 Million |
| Alcon AG (ALC) | $18.82 Billion | -2.82% | 0.47x | $37.83 Billion |
| Align Technology Inc (ALGN) | $93.44 Million | 1.51% | 0.52x | $11.30 Billion |
| AngioDynamics Inc (ANGO) | $405.75 Million | 2.00% | 0.08x | $353.07 Million |
| Ansell Limited (ANSLF) | $1.40 Billion | 7.95% | 0.69x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.24 Billion |
| AtriCure Inc (ATRC) | $15.61 Million | -34.94% | 1.17x | $1.46 Billion |
| Avinger Inc (AVGR) | $-6.20 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $1.86 Million | -634.53% | 4.26x | $156.14 Million |